What is HC Wainwright’s Forecast for Q32 Bio Q3 Earnings?

Q32 Bio Inc. (NASDAQ:QTTB) – Stock analysts at HC Wainwright lifted their Q3 2026 EPS estimates for Q32 Bio in a report released on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Q32 Bio’s Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.56) EPS.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.02.

Several other equities research analysts also recently issued reports on the company. Zacks Research downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Oppenheimer boosted their price objective on Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Mizuho started coverage on Q32 Bio in a report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price objective on the stock. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Finally, Cantor Fitzgerald started coverage on shares of Q32 Bio in a report on Monday, May 18th. They issued an “overweight” rating on the stock. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Q32 Bio has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Q32 Bio Stock Down 1.8%

Q32 Bio stock opened at $16.20 on Friday. Q32 Bio has a 1-year low of $1.57 and a 1-year high of $23.57. The firm has a market capitalization of $274.75 million, a price-to-earnings ratio of 5.40 and a beta of 0.23. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.04. The firm has a 50 day simple moving average of $13.85 and a 200 day simple moving average of $8.43.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc purchased 1,875,000 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were purchased at an average price of $8.00 per share, with a total value of $15,000,000.00. Following the acquisition, the director directly owned 3,502,987 shares of the company’s stock, valued at approximately $28,023,896. This represents a 115.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Diyong Xu acquired 1,875,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were bought at an average cost of $8.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the director directly owned 3,502,987 shares in the company, valued at $28,023,896. The trade was a 115.17% increase in their position. The disclosure for this purchase is available in the SEC filing. 34.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Q32 Bio

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in Q32 Bio in the 2nd quarter worth approximately $25,000. Acadian Asset Management LLC bought a new position in Q32 Bio during the first quarter valued at approximately $50,000. Two Sigma Investments LP bought a new position in Q32 Bio during the third quarter valued at approximately $62,000. ADAR1 Capital Management LLC purchased a new position in shares of Q32 Bio during the fourth quarter worth approximately $66,000. Finally, AQR Capital Management LLC purchased a new position in shares of Q32 Bio during the first quarter worth approximately $68,000. 31.32% of the stock is currently owned by institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.